Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctiontranscription coactivator activity

KAT6B SS18 MRTFB ZMIZ1 MED1

5.67e-06303185GO:0003713
GeneOntologyMolecularFunctionnuclear receptor coactivator activity

SS18 ZMIZ1 MED1

2.14e-0561183GO:0030374
GeneOntologyMolecularFunctionpromoter-specific chromatin binding

TAF1L SMAD3 MED1

5.40e-0583183GO:1990841
GeneOntologyMolecularFunctiontranscription coregulator activity

KAT6B SS18 MRTFB ZMIZ1 MED1

1.10e-04562185GO:0003712
GeneOntologyMolecularFunctionbitter taste receptor activity

TAS2R40 TAS2R39

2.66e-0427182GO:0033038
GeneOntologyMolecularFunctionchromatin binding

KAT6B TAF1L TNRC18 SMAD3 MED1

3.93e-04739185GO:0003682
GeneOntologyMolecularFunctiontaste receptor activity

TAS2R40 TAS2R39

3.99e-0433182GO:0008527
GeneOntologyMolecularFunctionnuclear receptor binding

TAF1L SMAD3 MED1

5.95e-04187183GO:0016922
GeneOntologyMolecularFunctionhistone acetyltransferase activity

KAT6B TAF1L

9.53e-0451182GO:0004402
GeneOntologyMolecularFunctiontranscription coactivator binding

SMAD3 MED1

1.07e-0354182GO:0001223
GeneOntologyMolecularFunctionpeptide-lysine-N-acetyltransferase activity

KAT6B TAF1L

1.11e-0355182GO:0061733
GeneOntologyMolecularFunctionpeptide N-acetyltransferase activity

KAT6B TAF1L

1.32e-0360182GO:0034212
GeneOntologyMolecularFunctiongeneral transcription initiation factor binding

TAF1L MED1

1.50e-0364182GO:0140296
GeneOntologyMolecularFunctionN-acetyltransferase activity

KAT6B TAF1L

2.21e-0378182GO:0008080
GeneOntologyMolecularFunctionSMAD binding

SMAD3 ZMIZ1

2.68e-0386182GO:0046332
GeneOntologyMolecularFunctionDNA-binding transcription repressor activity

TBX15 SMAD3 YLPM1

2.93e-03326183GO:0001217
GeneOntologyMolecularFunctionprotein-macromolecule adaptor activity

KAT6B SS18 MRTFB ZMIZ1 MED1

2.97e-031160185GO:0030674
GeneOntologyMolecularFunctionN-acyltransferase activity

KAT6B TAF1L

3.75e-03102182GO:0016410
GeneOntologyMolecularFunctionacetyltransferase activity

KAT6B TAF1L

3.89e-03104182GO:0016407
GeneOntologyMolecularFunctionacyltransferase activity

KAT6B TAF1L ZMIZ1 MED1

4.46e-03775184GO:0016746
GeneOntologyMolecularFunctionbeta-catenin binding

CXADR SMAD3

5.15e-03120182GO:0008013
GeneOntologyMolecularFunctionmolecular adaptor activity

KAT6B SS18 MRTFB ZMIZ1 MED1

5.83e-031356185GO:0060090
GeneOntologyMolecularFunctionRNA polymerase II-specific DNA-binding transcription factor binding

TAF1L SMAD3 MED1

5.84e-03417183GO:0061629
GeneOntologyMolecularFunctiontranscription coregulator binding

SMAD3 MED1

6.94e-03140182GO:0001221
GeneOntologyMolecularFunctionRNA polymerase II transcription regulatory region sequence-specific DNA binding

ZNF236 TBX15 TAF1L SMAD3 MED1

7.93e-031459185GO:0000977
GeneOntologyMolecularFunctionchromatin DNA binding

SMAD3 MED1

9.74e-03167182GO:0031490
GeneOntologyMolecularFunctionubiquitin-like protein transferase activity

TAF1L ZMIZ1 MED1

1.03e-02512183GO:0019787
GeneOntologyMolecularFunctionaminoacyltransferase activity

TAF1L ZMIZ1 MED1

1.14e-02532183GO:0016755
GeneOntologyBiologicalProcesspositive regulation of transcription by RNA polymerase II

KAT6B SS18 SSBP2 SMAD3 MRTFB ZMIZ1 MED1

6.63e-051390177GO:0045944
GeneOntologyBiologicalProcessheart morphogenesis

SMAD3 MRTFB ZMIZ1 MED1

1.17e-04321174GO:0003007
GeneOntologyBiologicalProcessstriated muscle tissue development

CXADR SMAD3 MRTFB MED1

1.61e-04349174GO:0014706
GeneOntologyBiologicalProcessregulation of striated muscle tissue development

SMAD3 MRTFB

1.90e-0425172GO:0016202
GeneOntologyBiologicalProcessheart development

CXADR SMAD3 MRTFB ZMIZ1 MED1

2.81e-04757175GO:0007507
GeneOntologyBiologicalProcessregulation of muscle organ development

SMAD3 MRTFB

2.93e-0431172GO:0048634
GeneOntologyBiologicalProcessliver development

SMAD3 MRTFB MED1

5.69e-04202173GO:0001889
GeneOntologyBiologicalProcessdetection of chemical stimulus involved in sensory perception of bitter taste

TAS2R40 TAS2R39

5.93e-0444172GO:0001580
GeneOntologyBiologicalProcesshepaticobiliary system development

SMAD3 MRTFB MED1

5.94e-04205173GO:0061008
GeneOntologyBiologicalProcesschordate embryonic development

TBX15 SMAD3 MRTFB ZMIZ1 MED1

6.43e-04906175GO:0043009
GeneOntologyBiologicalProcesssensory perception of bitter taste

TAS2R40 TAS2R39

7.05e-0448172GO:0050913
GeneOntologyBiologicalProcessembryo development ending in birth or egg hatching

TBX15 SMAD3 MRTFB ZMIZ1 MED1

7.21e-04929175GO:0009792
GeneOntologyBiologicalProcessdetection of chemical stimulus involved in sensory perception of taste

TAS2R40 TAS2R39

7.65e-0450172GO:0050912
GeneOntologyBiologicalProcessembryonic cranial skeleton morphogenesis

TBX15 SMAD3

8.28e-0452172GO:0048701
GeneOntologyBiologicalProcessmuscle tissue development

CXADR SMAD3 MRTFB MED1

9.53e-04558174GO:0060537
GeneOntologyBiologicalProcessembryonic organ development

TBX15 SMAD3 MRTFB MED1

9.72e-04561174GO:0048568
GeneOntologyBiologicalProcessregulation of muscle tissue development

SMAD3 MRTFB

9.94e-0457172GO:1901861
GeneOntologyBiologicalProcessprotein-DNA complex assembly

KAT6B TAF1L MED1

1.04e-03249173GO:0065004
GeneOntologyCellularComponentchromatin

TBX15 KAT6B SS18 TAF1L SMAD3 ZMIZ1 MED1

1.40e-041480187GO:0000785
HumanPhenoHypoplastic ischia

TBX15 KAT6B

9.20e-051652HP:0003175
HumanPhenoHypoplastic pubic bone

TBX15 KAT6B

1.45e-042052HP:0003173
HumanPhenoAplasia/Hypoplasia of the pubic bone

TBX15 KAT6B

1.61e-042152HP:0009104
MousePhenothin myocardium

CXADR MRTFB MED1

1.15e-0485163MP:0002652
MousePhenoabnormal embryonic tissue morphology

TBX15 SS18 CXADR MRTFB ZMIZ1 YLPM1 MED1

1.22e-041116167MP:0002085
MousePhenoabnormal placental labyrinth vasculature morphology

SS18 CXADR MED1

1.80e-0499163MP:0008803
MousePhenodilated dorsal aorta

CXADR ZMIZ1

1.86e-0418162MP:0004068
MousePhenopale yolk sac

MRTFB ZMIZ1 MED1

2.46e-04110163MP:0001722
MousePhenoincreased intestinal adenocarcinoma incidence

SSBP2 SMAD3

2.80e-0422162MP:0002957
MousePhenodecreased primary ovarian follicle number

RANBP9 SMAD3

3.93e-0426162MP:0011125
MousePhenoabnormal artery development

CXADR MRTFB ZMIZ1

4.31e-04133163MP:0003410
MousePhenoabnormal ear position

TBX15 KAT6B

4.56e-0428162MP:0000023
MousePhenoshortened head

TBX15 KAT6B

4.90e-0429162MP:0000435
MousePhenoabnormal primary ovarian follicle number

RANBP9 SMAD3

5.60e-0431162MP:0011123
MousePhenoabnormal angiogenesis

CXADR MRTFB ZMIZ1 MED1

6.97e-04372164MP:0000260
MousePhenoabnormal primary ovarian follicle morphology

RANBP9 SMAD3

7.15e-0435162MP:0009362
MousePhenoimpaired neutrophil chemotaxis

MPP1 SMAD3

9.34e-0440162MP:0008720
MousePhenoabnormal vein morphology

CXADR MRTFB MED1

9.74e-04176163MP:0002725
MousePhenoabnormal placenta vasculature

SS18 CXADR MED1

1.25e-03192163MP:0003231
MousePhenoabnormal pharyngeal arch artery morphology

MRTFB ZMIZ1

1.29e-0347162MP:0002672
MousePhenoabnormal placenta labyrinth morphology

SS18 CXADR MED1

1.29e-03194163MP:0001716
DomainT2R

TAS2R40 TAS2R39

2.81e-0426182IPR007960
DomainTAS2R

TAS2R40 TAS2R39

2.81e-0426182PF05296
DomainLisH

RANBP9 SSBP2

3.27e-0428182IPR006594
DomainLISH

RANBP9 SSBP2

3.27e-0428182PS50896
DomainLisH

RANBP9 SSBP2

3.27e-0428182SM00667
PathwayKEGG_TASTE_TRANSDUCTION

KCNB1 TAS2R40 TAS2R39

1.02e-0552123M5785
PathwayPID_AR_PATHWAY

RANBP9 ZMIZ1 MED1

1.65e-0561123M58
PathwayREACTOME_SENSORY_PERCEPTION_OF_TASTE

TAS2R40 TAS2R39

3.05e-0431122MM15691
PathwayREACTOME_CLASS_C_3_METABOTROPIC_GLUTAMATE_PHEROMONE_RECEPTORS

TAS2R40 TAS2R39

4.35e-0437122MM15067
PathwayREACTOME_CLASS_C_3_METABOTROPIC_GLUTAMATE_PHEROMONE_RECEPTORS

TAS2R40 TAS2R39

4.84e-0439122M793
PathwayREACTOME_SENSORY_PERCEPTION_OF_TASTE

TAS2R40 TAS2R39

7.03e-0447122M42524
Pubmed

Targeted disruption of the synovial sarcoma-associated SS18 gene causes early embryonic lethality and affects PPARBP expression.

SS18 MED1

7.59e-07318216926188
Pubmed

The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity.

SMAD3 ZMIZ1

2.53e-06518216777850
Pubmed

Amino acids important for ligand specificity of the human constitutive androstane receptor.

CXADR MED1

3.79e-06618215572376
Pubmed

Myocardin-like protein 2 regulates TGFβ signaling in embryonic stem cells and the developing vasculature.

SMAD3 MRTFB

7.07e-06818222899851
Pubmed

Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.

SSBP2 TNRC18 YLPM1 MED1

9.69e-0626818433640491
Pubmed

Mapping the Ku Interactome Using Proximity-Dependent Biotin Identification in Human Cells.

TAF1L MRTFB YLPM1 MED1

1.20e-0528318430585729
Pubmed

Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.

SMAD3 MED1

1.97e-051318219255064
Pubmed

Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.

KAT6B MRTFB YLPM1 MED1

2.49e-0534118432971831
Pubmed

Evolutionary relationships of the Tas2r receptor gene families in mouse and human.

TAS2R40 TAS2R39

5.81e-052218212734386
Pubmed

The molecular receptive ranges of human TAS2R bitter taste receptors.

TAS2R40 TAS2R39

6.36e-052318220022913
Pubmed

An atlas of combinatorial transcriptional regulation in mouse and man.

ZNF236 TBX15 SSBP2 SMAD3 MED1

6.57e-0587718520211142
Pubmed

Fibulin-4 deficiency results in ascending aortic aneurysms: a potential link between abnormal smooth muscle cell phenotype and aneurysm progression.

SMAD3 MRTFB

7.54e-052518220019329
Pubmed

Receptors for bitter and sweet taste.

TAS2R40 TAS2R39

7.54e-052518212139982
Pubmed

Molecular mechanisms of bitter and sweet taste transduction.

TAS2R40 TAS2R39

8.16e-052618211696554
Pubmed

Coding of sweet, bitter, and umami tastes: different receptor cells sharing similar signaling pathways.

TAS2R40 TAS2R39

8.81e-052718212581520
Pubmed

Lineage-specific loss of function of bitter taste receptor genes in humans and nonhuman primates.

TAS2R40 TAS2R39

9.49e-052818215744053
Pubmed

Adaptive diversification of bitter taste receptor genes in Mammalian evolution.

TAS2R40 TAS2R39

1.09e-043018212679530
Pubmed

Evolution of bitter taste receptors in humans and apes.

TAS2R40 TAS2R39

1.41e-043418215496549
Pubmed

Functional proteomics mapping of a human signaling pathway.

RANBP9 SMAD3 MRTFB YLPM1

2.09e-0459118415231748
Pubmed

Dominant and redundant functions of TFIID involved in the regulation of hepatic genes.

TAF1L MED1

2.26e-044318218722179
Pubmed

New nomenclature for chromatin-modifying enzymes.

KAT6B TAF1L

3.97e-045718218022353
Pubmed

Protein phosphatase 1γ isoforms linked interactions in the brain.

RANBP9 YLPM1

3.97e-045718223080069
InteractionAR interactions

RANBP9 SSBP2 TNRC18 SMAD3 ZMIZ1 YLPM1 MED1

8.63e-06992177int:AR
Cytoband7q34

TAS2R40 TAS2R39

1.94e-031671827q34
CytobandEnsembl 112 genes in cytogenetic band chr7q34

TAS2R40 TAS2R39

2.37e-03185182chr7q34
CytobandEnsembl 112 genes in cytogenetic band chr10q22

KAT6B ZMIZ1

2.98e-03208182chr10q22
GeneFamilyTaste 2 receptors

TAS2R40 TAS2R39

3.48e-04391321162
CoexpressionDAZARD_UV_RESPONSE_CLUSTER_G6

KAT6B SSBP2 SMAD3 ZMIZ1

2.59e-06145184M1810
CoexpressionDAZARD_RESPONSE_TO_UV_NHEK_DN

KAT6B SSBP2 SMAD3 ZMIZ1

4.54e-05300184M8702
CoexpressionNAKAYA_B_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP

ZNF236 RANBP9 YLPM1 MED1

9.91e-05367184M41159
CoexpressionDACOSTA_UV_RESPONSE_VIA_ERCC3_DN

KAT6B SSBP2 SMAD3 ZMIZ1 MED1

2.21e-04856185M4500
CoexpressionGSE41176_UNSTIM_VS_ANTI_IGM_STIM_BCELL_3H_DN

SSBP2 CXADR MRTFB

3.14e-04197183M9916
CoexpressionGSE26928_NAIVE_VS_CXCR5_POS_CD4_TCELL_UP

TAF1L SSBP2 MRTFB

3.14e-04197183M4682
CoexpressionGSE9988_ANTI_TREM1_VS_VEHICLE_TREATED_MONOCYTES_DN

TNRC18 SMAD3 MRTFB

3.14e-04197183M5853
CoexpressionGSE14350_TREG_VS_TEFF_UP

MPP1 SSBP2 SMAD3

3.23e-04199183M3417
CoexpressionGSE39820_TGFBETA3_IL6_VS_TGFBETA3_IL6_IL23A_TREATED_CD4_TCELL_UP

SS18 SMAD3 ZMIZ1

3.23e-04199183M5620
CoexpressionGSE46606_IRF4HIGH_VS_WT_CD40L_IL2_IL5_DAY1_STIMULATED_BCELL_UP

RANBP9 SS18 TNRC18

3.28e-04200183M9847
CoexpressionGSE37534_GW1929_VS_PIOGLITAZONE_TREATED_CD4_TCELL_PPARG1_FOXP3_TRANSDUCED_DN

SS18 CXADR MRTFB

3.28e-04200183M8986
CoexpressionGSE21670_STAT3_KO_VS_WT_CD4_TCELL_TGFB_IL6_TREATED_DN

MPP1 SSBP2 ZMIZ1

3.28e-04200183M7453
CoexpressionTIEN_INTESTINE_PROBIOTICS_24HR_DN

ZNF236 RANBP9 KAT6B

4.05e-04215183M19666
CoexpressionONKEN_UVEAL_MELANOMA_DN

SS18 SSBP2 CXADR YLPM1

4.12e-04533184M2605
CoexpressionAtlasDevelopingKidney_e14.5 whole kidney - Wnt4 KO_emap-6674_k-means-cluster#4_top-relative-expression-ranked_200

SSBP2 MED1

5.56e-0516152gudmap_developingKidney_e14.5 whole kidney - Wnt4 KO_200_k4
CoexpressionAtlasDevelopingKidney_e14.5 whole kidney - Wnt4 KO_emap-6674_top-relative-expression-ranked_1000

RANBP9 KAT6B SSBP2 YLPM1 MED1

1.56e-04791155gudmap_developingKidney_e14.5 whole kidney - Wnt4 KO_1000
CoexpressionAtlasDevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_top-relative-expression-ranked_1000

TBX15 KAT6B SSBP2 CXADR YLPM1

2.02e-04836155gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_1000
CoexpressionAtlasdev gonad_e11.5_F_GonMes_Sma_top-relative-expression-ranked_1000

KAT6B SSBP2 TNRC18 CXADR SMAD3

2.28e-04858155gudmap_dev gonad_e11.5_F_GonMes_Sma_1000
CoexpressionAtlasDevelopingKidney_e14.5 whole kidney - Wnt4 KO_emap-6674_k-means-cluster#2_top-relative-expression-ranked_500

SSBP2 MED1

3.06e-0437152gudmap_developingKidney_e14.5 whole kidney - Wnt4 KO_500_k2
CoexpressionAtlasDevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_k-means-cluster#5_top-relative-expression-ranked_1000

TBX15 SSBP2 CXADR YLPM1

3.17e-04492154gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_1000_k5
CoexpressionAtlasDevelopingKidney_e15.5_stage III -IV renal corpusc_emap-27945_k-means-cluster#5_top-relative-expression-ranked_1000

SSBP2 CXADR ZMIZ1

4.93e-04226153gudmap_developingKidney_e15.5_stage III -IV renal corpusc_1000_k5
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ZNF236 KAT6B SMAD3 ZMIZ1

7.70e-061661842247_DN
Drugirinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A

KAT6B SMAD3 MRTFB ZMIZ1

8.66e-061711847535_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ZNF236 KAT6B SMAD3 ZMIZ1

8.86e-061721843428_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ZNF236 KAT6B SMAD3 ZMIZ1

1.01e-051781841672_DN
DrugPerhexiline maleate [6724-53-4]; Up 200; 10.2uM; HL60; HT_HG-U133A

SS18 SSBP2 SMAD3 MRTFB

1.06e-051801842410_UP
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A

ZNF236 KAT6B SMAD3 MED1

1.06e-051801846886_DN
DrugPhenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A

KAT6B SSBP2 MRTFB YLPM1

1.13e-051831845613_DN
DrugKaempferol [520-18-3]; Down 200; 14uM; MCF7; HT_HG-U133A

KAT6B SSBP2 SMAD3 YLPM1

1.42e-051941847196_DN
DrugMethyldopa (L,-) [555-30-6]; Up 200; 19uM; PC3; HT_HG-U133A

ZNF236 KCNB1 SS18 SMAD3

1.61e-052001844677_UP
Drugretinoic acid; Up 200; 1uM; MCF7; HT_HG-U133A_EA

KAT6B SMAD3 ZMIZ1

2.57e-041601831049_UP
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

2.72e-041631835594_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

2.82e-041651836085_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

2.82e-041651832835_DN
Drugretinoic acid; Up 200; 1uM; MCF7; HT_HG-U133A_EA

KAT6B SMAD3 ZMIZ1

2.92e-04167183966_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

2.97e-041681833868_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ZNF236 KAT6B SMAD3

2.97e-041681833395_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.02e-041691836064_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.02e-041691835231_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

KAT6B SMAD3 ZMIZ1

3.07e-041701831050_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.18e-041721837179_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA

KAT6B SMAD3 ZMIZ1

3.18e-041721831072_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.18e-041721834112_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

KAT6B SS18 SMAD3

3.23e-041731834237_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.29e-041741833462_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.29e-041741831659_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.29e-041741835693_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

KAT6B SS18 MED1

3.29e-041741835065_DN
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.40e-041761835976_DN
DrugSAHA; Down 200; 10uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.40e-041761836980_DN
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A

KAT6B SS18 ZMIZ1

3.40e-041761837499_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.40e-041761836784_DN
DrugSAHA; Down 200; 10uM; MCF7; HT_HG-U133A

ZNF236 KAT6B ZMIZ1

3.46e-041771831645_DN
DrugPhenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A

SS18 MRTFB YLPM1

3.46e-041771834652_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.57e-041791835484_DN
DrugCamptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A

KAT6B MRTFB ZMIZ1

3.63e-041801834541_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.63e-041801834821_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.69e-041811833643_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.69e-041811836951_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ZNF236 KAT6B SMAD3

3.75e-041821835802_DN
DrugZuclopenthixol hydrochloride [633-59-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A

RANBP9 SS18 SMAD3

3.81e-041831834843_UP
DrugSAHA; Down 200; 10uM; MCF7; HT_HG-U133A

KAT6B SMAD3 ZMIZ1

3.87e-041841836939_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

KAT6B SMAD3 YLPM1

3.87e-041841831064_DN
Drugretinoic acid; Up 200; 1uM; MCF7; HT_HG-U133A

SMAD3 YLPM1 MED1

3.94e-041851836931_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

KAT6B YLPM1 MED1

4.06e-041871834302_DN
DrugGinkgolide A [15291-75-5]; Down 200; 9.8uM; MCF7; HT_HG-U133A

RANBP9 SS18 SMAD3

4.19e-041891834121_DN
Drugretinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A

RANBP9 SS18 SSBP2

4.26e-041901831636_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

KAT6B SS18 SMAD3

4.26e-041901836709_DN
DrugAzacytidine-5 [320-67-2]; Down 200; 16.4uM; PC3; HT_HG-U133A

KAT6B SS18 SMAD3

4.26e-041901834010_DN
DrugLY 294002; Up 200; 10uM; MCF7; HT_HG-U133A

SS18 SMAD3 YLPM1

4.26e-041901836956_UP
DrugFludrocortisone acetate [514-36-3]; Up 200; 9.4uM; HL60; HT_HG-U133A

ZNF236 SS18 MRTFB

4.32e-041911832368_UP
DrugPNU-0230031 [267429-39-0]; Down 200; 10uM; PC3; HT_HG-U133A

MPP1 SSBP2 SMAD3

4.39e-041921834288_DN
DrugSalsolinol hydrobromide [38221-21-5]; Down 200; 15.4uM; MCF7; HT_HG-U133A

RANBP9 SS18 SSBP2

4.39e-041921834816_DN
DrugD-cycloserine [68-41-7]; Down 200; 39.2uM; MCF7; HT_HG-U133A

SS18 SSBP2 MED1

4.46e-041931833562_DN
Drugtrichostatin A; Down 200; 0.1uM; ssMCF7; HG-U133A

KAT6B SMAD3 ZMIZ1

4.46e-04193183413_DN
DrugNocodazole [31430-18-9]; Down 200; 13.2uM; PC3; HT_HG-U133A

RANBP9 KAT6B SMAD3

4.46e-041931832076_DN
Drug17-DMAG; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

KAT6B SMAD3 ZMIZ1

4.46e-041931831051_DN
DrugAlthiazide [5588-16-9]; Up 200; 10.4uM; HL60; HT_HG-U133A

KCNB1 SMAD3 YLPM1

4.52e-041941832527_UP
Drug11-deoxy-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A

MPP1 KAT6B SS18

4.52e-041941837538_DN
DrugRoxithromycin [80214-83-1]; Down 200; 4.8uM; PC3; HT_HG-U133A

RANBP9 SS18 SSBP2

4.52e-041941834192_DN
Drug2-propylpentanoic acid; Down 200; 50uM; HL60; HT_HG-U133A

ZNF236 SMAD3 MED1

4.59e-041951831163_DN
DrugHomochlorcyclizine dihydrochloride [1982-36-1]; Up 200; 10.4uM; HL60; HT_HG-U133A

SS18 SSBP2 SMAD3

4.59e-041951832386_UP
DrugTinidazole [19387-91-8]; Down 200; 16.2uM; HL60; HT_HG-U133A

RANBP9 SS18 SSBP2

4.59e-041951832568_DN
DrugHexylcaine hydrochloride [532-76-3]; Down 200; 13.4uM; HL60; HT_HG-U133A

KAT6B SMAD3 MED1

4.59e-041951832708_DN
Drugnordihydroguaiaretic acid; Up 200; 1uM; MCF7; HT_HG-U133A

SS18 YLPM1 MED1

4.66e-041961836942_UP
DrugSulfameter [651-06-9]; Down 200; 14.2uM; MCF7; HT_HG-U133A

SS18 SMAD3 YLPM1

4.66e-041961833453_DN
DrugAcyclovir [59277-89-3]; Up 200; 17.8uM; PC3; HT_HG-U133A

ZNF236 SS18 SMAD3

4.66e-041961834683_UP
DrugAzathymine, 6 [932-53-6]; Down 200; 31.4uM; MCF7; HT_HG-U133A

SS18 SMAD3 MED1

4.66e-041961832827_DN
Drug17-AAG; Up 200; 1uM; PC3; HT_HG-U133A

ZNF236 KCNB1 YLPM1

4.66e-041961835919_UP
DrugMuramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; HL60; HT_HG-U133A

KAT6B SS18 SMAD3

4.66e-041961831326_UP
DrugCAY10397; Down 200; 10uM; PC3; HT_HG-U133A

RANBP9 KAT6B SSBP2

4.66e-041961837087_DN
DrugLetrozole [112809-51-5]; Up 200; 14uM; MCF7; HT_HG-U133A

RANBP9 SS18 SSBP2

4.66e-041961834824_UP
Drug(-)-depudecin; Down 200; 1uM; MCF7; HT_HG-U133A_EA

KAT6B SS18 SMAD3

4.66e-04196183874_DN
Drugstaurosporine; Down 200; 0.01uM; SKMEL5; HG-U133A

SMAD3 YLPM1 MED1

4.66e-04196183508_DN
DrugTrimeprazine tartrate [4330-99-8]; Down 200; 5.4uM; HL60; HT_HG-U133A

KAT6B SMAD3 YLPM1

4.66e-041961832736_DN
DrugFlorfenicol [73231-34-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A

RANBP9 SS18 SSBP2

4.66e-041961836460_DN
DrugSulfachloropyridazine [80-32-0]; Down 200; 14uM; PC3; HT_HG-U133A

SS18 SSBP2 SMAD3

4.73e-041971833769_DN
DrugAllantoin [97-59-6]; Up 200; 25.2uM; MCF7; HT_HG-U133A

ZNF236 SMAD3 MED1

4.73e-041971831678_UP
DrugBupropion hydrochloride [31677-93-7]; Up 200; 14.4uM; HL60; HG-U133A

SSBP2 SMAD3 MED1

4.73e-041971831564_UP
DrugTiclopidine hydrochloride [53885-35-1]; Down 200; 13.4uM; HL60; HG-U133A

ZNF236 KAT6B MED1

4.73e-041971831975_DN
DrugDemeclocycline hydrochloride [64-73-3]; Down 200; 8uM; MCF7; HT_HG-U133A

SS18 SMAD3 YLPM1

4.73e-041971833404_DN
DrugN-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Down 200; 25.2uM; HL60; HT_HG-U133A

KAT6B SS18 MRTFB

4.73e-041971832176_DN
DrugMoxisylyte hydrochoride [964-52-3]; Up 200; 12.6uM; MCF7; HT_HG-U133A

KCNB1 KAT6B SMAD3

4.73e-041971831682_UP
DrugEserine sulfate, physostigmine sulfate [64-47-1]; Up 200; 6.2uM; HL60; HG-U133A

KAT6B SMAD3 YLPM1

4.73e-041971831776_UP
DrugIproniazide phosphate [305-33-9]; Down 200; 14.4uM; PC3; HT_HG-U133A

SS18 SSBP2 YLPM1

4.73e-041971836359_DN
DrugTrichlorfon [52-68-6]; Down 200; 15.6uM; PC3; HT_HG-U133A

KAT6B SS18 YLPM1

4.80e-041981831797_DN
Drugclozapine; Down 200; 10uM; HL60; HT_HG-U133A

ZNF236 KAT6B MRTFB

4.80e-041981831170_DN
DrugSpectinomycin dihydrochloride [21736-83-4]; Down 200; 9.8uM; MCF7; HT_HG-U133A

KAT6B SS18 YLPM1

4.80e-041981834773_DN
DrugBacitracin [1405-87-4]; Down 200; 2.8uM; MCF7; HT_HG-U133A

ZNF236 SS18 YLPM1

4.80e-041981836488_DN
DrugEnalapril maleate [76095-16-4]; Up 200; 8.2uM; HL60; HT_HG-U133A

SS18 MRTFB YLPM1

4.80e-041981832397_UP
DrugDihydrostreptomycin sulfate [5490-27-7]; Down 200; 2.8uM; MCF7; HT_HG-U133A

KAT6B SSBP2 MED1

4.80e-041981836228_DN
Drugnovobiocin sodium, USP; Up 200; 100uM; SKMEL5; HG-U133A

MPP1 YLPM1 MED1

4.80e-04198183632_UP
DrugChenodiol [474-25-9]; Up 200; 10.2uM; HL60; HT_HG-U133A

SS18 SSBP2 MRTFB

4.80e-041981832402_UP
DrugFenofibrate [49562-28-9]; Down 200; 11uM; HL60; HT_HG-U133A

KAT6B SS18 SMAD3

4.80e-041981832401_DN
DrugNitrocaramiphen hydrochloride; Down 200; 10.8uM; MCF7; HT_HG-U133A

ZNF236 SS18 SMAD3

4.80e-041981836504_DN
Drug(-)-Cinchonidine [485-71-2]; Up 200; 13.6uM; HL60; HG-U133A

ZNF236 SS18 YLPM1

4.87e-041991831780_UP
DrugMeropenem [96036-03-2]; Down 200; 10.4uM; MCF7; HT_HG-U133A

SS18 SMAD3 YLPM1

4.87e-041991833564_DN
Drugestradiol, USP; Down 200; 0.01uM; MCF7; HT_HG-U133A

SSBP2 SMAD3 YLPM1

4.87e-041991835601_DN
DrugTrimetazidine dihydrochloride [13171-25-0]; Down 200; 11.8uM; HL60; HG-U133A

RANBP9 SS18 SSBP2

4.87e-041991831727_DN
Drugalpha-estradiol; Down 200; 0.01uM; PC3; HT_HG-U133A

MPP1 SSBP2 YLPM1

4.87e-041991831210_DN
DrugPrenylamine lactate [69-43-2]; Down 200; 9.6uM; HL60; HG-U133A

SSBP2 YLPM1 MED1

4.87e-041991831737_DN
Diseasediastolic blood pressure, systolic blood pressure

RANBP9 TBX15 KCNB1 SMAD3

6.26e-04670184EFO_0006335, EFO_0006336
Diseasebreast size

TBX15 KAT6B

8.05e-0469182EFO_0004884
Diseaseautoimmune thyroid disease, systemic lupus erythematosus, type 1 diabetes mellitus, ankylosing spondylitis, psoriasis, common variable immunodeficiency, celiac disease, ulcerative colitis, Crohn's disease, autoimmune disease, juvenile idiopathic arthritis

SMAD3 ZMIZ1

8.28e-0470182EFO_0000384, EFO_0000676, EFO_0000729, EFO_0001060, EFO_0002609, EFO_0003898, EFO_0005140, EFO_0006812, MONDO_0005147, MONDO_0007915, MONDO_0015517
Diseaseleft ventricular structural measurement

KAT6B SS18

1.30e-0388182EFO_0008205
Diseasesmoking behavior, BMI-adjusted waist circumference

TBX15 SMAD3

2.48e-03122182EFO_0004318, EFO_0007789
DiseaseBMI-adjusted waist circumference, physical activity measurement

TBX15 ZMIZ1

2.52e-03123182EFO_0007789, EFO_0008002
DiseasePolyarthritis, Juvenile, Rheumatoid Factor Positive

KAT6B SMAD3

2.86e-03131182C4704862
DiseasePolyarthritis, Juvenile, Rheumatoid Factor Negative

KAT6B SMAD3

2.86e-03131182C4552091
DiseaseJuvenile arthritis

KAT6B SMAD3

2.86e-03131182C3495559
DiseaseJuvenile psoriatic arthritis

KAT6B SMAD3

2.86e-03131182C3714758
Diseasebreast carcinoma

RANBP9 SSBP2 SMAD3 ZMIZ1

2.94e-031019184EFO_0000305
DiseaseJuvenile-Onset Still Disease

KAT6B SMAD3

3.03e-03135182C0087031
Diseasenasopharyngeal neoplasm

SMAD3 MED1

3.77e-03151182EFO_0004252
Diseasecolorectal cancer, colorectal adenoma

SMAD3 ZMIZ1

3.82e-03152182EFO_0005406, MONDO_0005575
Diseaseelectrocardiography

KAT6B SMAD3 ZMIZ1

3.85e-03530183EFO_0004327
DiseaseCraniofacial Abnormalities

TBX15 SMAD3

4.02e-03156182C0376634
Diseaseanthropometric measurement

TBX15 ZMIZ1

4.64e-03168182EFO_0004302
Diseasebipolar disorder

KCNB1 SSBP2 ZMIZ1

4.88e-03577183MONDO_0004985
Diseasevital capacity

TBX15 SMAD3 ZMIZ1 MED1

5.85e-031236184EFO_0004312
Diseaseatopic asthma

SMAD3 MED1

6.45e-03199182EFO_0010638
Diseasewellbeing measurement

KCNB1 SMAD3 YLPM1

8.06e-03692183EFO_0007869
Diseasebalding measurement

TBX15 SMAD3 ZMIZ1

1.16e-02792183EFO_0007825
DiseaseColorectal Neoplasms

SMAD3 ZMIZ1

1.22e-02277182C0009404

Protein segments in the cluster

PeptideGeneStartEntry
FSSPSMSPSHGMNIH

RANBP9

481

Q96S59
PGHHGYMNTGMSKQS

KAT6B

2051

Q8WYB5
HSGMLDHSHSPMETS

MRTFB

1011

Q9ULH7
MPAGMTKHGSRSTSS

KCNB1

1

Q14721
GSNHSSLGSMSPSNM

CXADR

296

P78310
MTLKASEGESGGSMH

MPP1

1

Q00013
GSHMSGTSSSSGMKS

MED1

1231

Q15648
SSHPMSSKHNMSGGE

MED1

1336

Q15648
HMGSNATGSNDPSME

TAS2R39

241

P59534
HMGSNATGSRDPSMK

TAS2R40

226

P59535
ESHHMNGSLGSGDMD

SSBP2

301

P81877
MSTEQAHSGEGPMSK

TAF1L

1051

Q8IZX4
SSPHMFGGSHMQQSS

TBX15

491

Q96SF7
DMHSAAHGSGEASAM

TNRC18

571

O15417
TSDHQMNHSMDAGSP

SMAD3

191

P84022
NMPSSSHGSMGGYNH

SS18

151

Q15532
PSSHHSSEMMGSDAS

YLPM1

1421

P49750
KMHMGGPQNSTSSTE

ZNF236

306

Q9UL36
SMSSMKPTLSHSDGS

ZMIZ1

131

Q9ULJ6